GSA Capital Partners’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

GSA Capital Partners’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-24,008	Closed	-$101K	–	1984
2018 Q3	$101K	Sell	24,008 -12,964	-35%	-$54.6K	0.01%	1559
2018 Q2	$143K	Buy	+36,972	New	+$245K	0.01%	1573
2016 Q2	–	Sell	-1,723	Closed	-$113K	–	2025
2016 Q1	$113K	Buy	+1,723	New	+$89.9K	0.01%	1571
2015 Q3	–	Sell	-31,910	Closed	-$3.1M	–	2197
2015 Q2	$3.1M	Buy	31,910 +11,959	+60%	+$1.14M	0.12%	162
2015 Q1	$1.86M	Buy	+19,951	New	+$1.7M	0.07%	386
2014 Q4	–	Sell	-9,514	Closed	-$657K	–	2034
2014 Q3	$657K	Buy	9,514 +3,241	+52%	+$173K	0.03%	759
2014 Q2	$360K	Buy	+6,273	New	+$319K	0.02%	1329

Other funds holding MACK

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GSA Capital Partners's MACK Position: Q4 2018 in Review

GSA Capital Partners sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2018, closing a stake of 24,008 shares — an estimated $101K sold.

GSA Capital Partners first reported a position in MACK in Q2 2014 and held it in 7 quarters. The position peaked at $3.1M in Q2 2015. 56 funds tracked by Wall St. Rank hold MACK as of Q4 2018.

GSA Capital Partners reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
GSA Capital Partners sold 24,008 Merrimack Pharmaceuticals, Inc. shares in Q4 2018, an estimated $101K.
GSA Capital Partners first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2014 and held it in 7 quarters.
GSA Capital Partners's Merrimack Pharmaceuticals, Inc. position peaked at $3.1M in Q2 2015.
56 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2018.

Based on GSA Capital Partners's 13F filing for Q4 2018, filed 12 Feb 2019.